In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Serum omentin significantly predicts cardiovascular events both in patients with the metabolic syndrome and in subjects who do not have the metabolic syndrome

Session Poster Session 1

Speaker Christoph Saely

Event : ESC Congress 2013

  • Topic : preventive cardiology
  • Sub-topic : Obesity
  • Session type : Poster Session

Authors : CH Saely (Fedlkirch,AT), A Leiherer (Feldkirch,AT), A Muendlein (Feldkirch,AT), A Vonbank (Triesen,LI), D Zanolin (Feldkirch,AT), K Geiger (Feldkirch,AT), H Drexel (Philadelphia,US)

Authors:
C.H. Saely1 , A. Leiherer2 , A. Muendlein2 , A. Vonbank3 , D. Zanolin2 , K. Geiger2 , H. Drexel4 , 1Academic Teaching Hospital, Department of Internal Medicine - Fedlkirch - Austria , 2VIVIT Institute - Feldkirch - Austria , 3Private University of the Principality of Liechtenstein - Triesen - Liechtenstein , 4Drexel University College of Medicine - Philadelphia - United States of America ,

Citation:
European Heart Journal ( 2013 ) 34 ( Abstract Supplement ), 143-144

Purpose: Some recent small cross-sectional studies have described associations of the novel adipocytokine omentin with atherosclerosis. However, no prospective data on the power of omentin to predict cardiovascular events are available.

Methods: We therefore measured serum omentin in a series of 297 patients undergoing coronary angiography for the evaluation of established or suspected stable CAD; the metabolic syndrome (MetS) was defined according to national cholesterol education programme adult treatment panel III criteria; cardiovascular events were recorded over a mean follow-up period of 3.2 years.

Results: During the follow-up period, 18.4% of our patients suffered cardiovascular events, corresponding to an annual event rate of 5.8%. In the total study population, serum omentin significantly predicted cardiovascular events both univariately (standardized adjusted HR 1.47 [1.21-1.78]; p <0.001) and after adjustment for age, gender, BMI, diabetes, hypertension, LDL cholesterol, HDL cholesterol and smoking (HR 1.49 [1.21-1.82]; p<0.001). From our patients, 98 had the MetS and 199 did not have the MetS. In both of these patient subgroups serum omentin strongly predicted cardiovascular events both univariately (HRs 1.51 [1.15-2.00]; p=0.003 and 1.41 [1.08-1.84]; p=0.011, respectively) and after adjustment for age, gender, BMI, diabetes, hypertension, LDL cholesterol, HDL cholesterol and smoking (1.56 [1.09-2.25]; p=0.016 and 1.48 [1.12-1.97]; p=0.006, respectively).

Conclusions: From this first prospective evaluation of the cardiovascular risk associated with serum omentin we conclude that elevated serum omentin is a strong predictor of cardiovascular events both among patients with the MetS and among subjects who do not have the MetS.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are